ES2953017T3 - Dispositivo de tira de inmunoensayo de flujo lateral - Google Patents
Dispositivo de tira de inmunoensayo de flujo lateral Download PDFInfo
- Publication number
- ES2953017T3 ES2953017T3 ES19713506T ES19713506T ES2953017T3 ES 2953017 T3 ES2953017 T3 ES 2953017T3 ES 19713506 T ES19713506 T ES 19713506T ES 19713506 T ES19713506 T ES 19713506T ES 2953017 T3 ES2953017 T3 ES 2953017T3
- Authority
- ES
- Spain
- Prior art keywords
- sample
- conjugate
- target peptide
- particle
- pad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003018 immunoassay Methods 0.000 title description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 100
- 239000002245 particle Substances 0.000 claims abstract description 74
- 239000012528 membrane Substances 0.000 claims abstract description 42
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- 238000003556 assay Methods 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 238000011068 loading method Methods 0.000 claims abstract description 26
- 238000001514 detection method Methods 0.000 claims abstract description 25
- 239000007787 solid Substances 0.000 claims abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 20
- 108700021042 biotin binding protein Proteins 0.000 claims abstract description 18
- 102000043871 biotin binding protein Human genes 0.000 claims abstract description 18
- 239000002250 absorbent Substances 0.000 claims abstract description 15
- 230000002745 absorbent Effects 0.000 claims abstract description 15
- 238000012360 testing method Methods 0.000 claims description 43
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 38
- 229920002674 hyaluronan Polymers 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 27
- 239000002105 nanoparticle Substances 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 108010087904 neutravidin Proteins 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 20
- 229940098773 bovine serum albumin Drugs 0.000 claims description 20
- 201000008482 osteoarthritis Diseases 0.000 claims description 20
- 210000002700 urine Anatomy 0.000 claims description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- 229940072322 hylan Drugs 0.000 claims description 14
- 102000000503 Collagen Type II Human genes 0.000 claims description 10
- 108010041390 Collagen Type II Proteins 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 10
- 238000004393 prognosis Methods 0.000 claims description 10
- 239000003932 viscosupplement Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 108090001008 Avidin Proteins 0.000 claims description 7
- 230000008355 cartilage degradation Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 4
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 3
- 239000000523 sample Substances 0.000 description 117
- 239000000562 conjugate Substances 0.000 description 87
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 40
- 239000010931 gold Substances 0.000 description 37
- 229910052737 gold Inorganic materials 0.000 description 37
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 26
- 229960002685 biotin Drugs 0.000 description 20
- 235000020958 biotin Nutrition 0.000 description 20
- 239000011616 biotin Substances 0.000 description 20
- 239000011248 coating agent Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- 230000027455 binding Effects 0.000 description 14
- 229940109239 creatinine Drugs 0.000 description 14
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 12
- 229940099552 hyaluronan Drugs 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 229940036220 synvisc Drugs 0.000 description 9
- -1 poly(vinylidene fluoride) Polymers 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000015100 cartilage disease Diseases 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000000863 peptide conjugate Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000002967 competitive immunoassay Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012125 lateral flow test Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 208000016247 Soft tissue disease Diseases 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000011852 carbon nanoparticle Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Metal Rolling (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18165380 | 2018-04-03 | ||
| PCT/EP2019/058224 WO2019192978A1 (en) | 2018-04-03 | 2019-04-02 | Lateral flow immunoassay strip device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2953017T3 true ES2953017T3 (es) | 2023-11-07 |
Family
ID=61868418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19713506T Active ES2953017T3 (es) | 2018-04-03 | 2019-04-02 | Dispositivo de tira de inmunoensayo de flujo lateral |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12123873B2 (https=) |
| EP (1) | EP3775896B1 (https=) |
| JP (1) | JP2021520484A (https=) |
| CN (1) | CN111868528B (https=) |
| ES (1) | ES2953017T3 (https=) |
| WO (1) | WO2019192978A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232313A1 (en) * | 2019-05-14 | 2020-11-19 | Inscent, Inc. | Lateral flow device for target analyte detection using chemosensory proteins |
| JP7540903B2 (ja) * | 2020-06-19 | 2024-08-27 | デンカ株式会社 | 流路とコロイド粒子を用いた被検物質検出方法 |
| EP4260065A1 (en) * | 2020-12-11 | 2023-10-18 | Huvepharma Inc. | Lateral flow assay for detection of monensin |
| CN117940772A (zh) | 2021-05-18 | 2024-04-26 | 2Pi西格玛公司 | 使用对含有目标分析物的外泌体具有特异性的抗体的夹心免疫测定装置 |
| CN114002443A (zh) * | 2021-11-03 | 2022-02-01 | 厦门宝太生物科技股份有限公司 | 可滤血色素冻干球均相发光免疫检测试剂盒及其制备方法 |
| CN115792241B (zh) * | 2022-11-23 | 2024-07-23 | 弗雷米德生物医药技术（天津）有限公司 | 一种宫颈癌e7蛋白检测抗体抗原的检测盒及其检测方法 |
| CN120936877A (zh) * | 2023-03-21 | 2025-11-11 | 新生命医药科技有限公司 | 用于前列腺癌筛查的基于侧流免疫测定的精胺快速检测 |
| TW202528550A (zh) * | 2023-11-09 | 2025-07-16 | 香港大學 | 用於非侵入性快速測試鼻咽癌中存在之ｄｎａ、ｒｎａ及蛋白質標記之組合物及方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2868900B2 (ja) * | 1991-01-11 | 1999-03-10 | クイデル コーポレイション | ワンステップ側方流非吸収性アッセイ |
| US5374561A (en) | 1993-10-25 | 1994-12-20 | Miles Inc. | Oxidative creatinine assay |
| US7635597B2 (en) * | 1995-08-09 | 2009-12-22 | Bayer Healthcare Llc | Dry reagent particle assay and device having multiple test zones and method therefor |
| US6979576B1 (en) | 1997-07-25 | 2005-12-27 | Shu-Ching Cheng | Methods of use of one step immunochromatographic device for Streptococcus A antigen |
| US6001656A (en) | 1998-09-28 | 1999-12-14 | Bayer Corporation | Method for the detection of creatinine |
| US20070004658A1 (en) * | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| PT1835923E (pt) | 2004-12-30 | 2013-11-04 | Genzyme Corp | Regimes para viscossuplementação intra-articular |
| JP4694952B2 (ja) * | 2005-11-17 | 2011-06-08 | 旭化成株式会社 | 標識付き試薬を用いた分析方法、分析装置 |
| ATE440609T1 (de) * | 2006-05-11 | 2009-09-15 | Sandra Gobbo | Binäre hyaluronsäure-gemische und ihre therapeutische verwendung |
| CN200968955Y (zh) * | 2006-07-26 | 2007-10-31 | 艾博生物医药(杭州)有限公司 | 生物液体样本分析装置 |
| JP5224477B2 (ja) * | 2006-11-01 | 2013-07-03 | ベックマン コールター， インコーポレイテッド | 親和性アッセイのための結合表面 |
| US20080138842A1 (en) * | 2006-12-11 | 2008-06-12 | Hans Boehringer | Indirect lateral flow sandwich assay |
| CN101363849A (zh) * | 2008-09-24 | 2009-02-11 | 深圳市菲鹏生物股份有限公司 | 间接标记纳米颗粒的抗体检测捕获法及其试剂盒 |
| CN102650638B (zh) * | 2011-02-25 | 2015-11-04 | 广州固康生物科技有限公司 | 尿中ii型胶原降解产物检测试剂盒及其制备方法 |
| CH705758B1 (fr) * | 2011-11-15 | 2016-03-31 | Metalor Technologies Int | Nanoparticules cœur-coquille métal-silice, procédé de fabrication et dispositif de test par immunochromatographie comprenant de telles nanoparticules. |
| CN102445537A (zh) * | 2011-12-20 | 2012-05-09 | 广州万孚生物技术有限公司 | 一种甲型流感病毒抗原和乙型病毒流感抗原的联检试纸及其制备方法 |
| BR112015008036B1 (pt) | 2012-10-11 | 2022-09-13 | Zoetis Services Llc | População de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica, método para detectar a presença de anticorpos e kit |
| CN103913568A (zh) * | 2013-01-04 | 2014-07-09 | 广州万孚生物技术股份有限公司 | 一种人体自身抗体联检试纸条及其制备方法 |
| JP6605792B2 (ja) * | 2013-08-07 | 2019-11-13 | 古河電気工業株式会社 | 複合標識粒子、これを用いた標的物質の検出方法、コロイド液および標識試薬、ならびに複合標識粒子の製造方法 |
| JP6440166B2 (ja) * | 2014-03-28 | 2018-12-19 | 大日本塗料株式会社 | イムノクロマトキット |
| CN103954772B (zh) * | 2014-04-30 | 2016-05-11 | 广东海大畜牧兽医研究院有限公司 | 一种猪瘟病毒、猪繁殖与呼吸障碍综合征病毒、伪狂犬病毒抗体的三联金标检测试纸条 |
| CN107206040A (zh) | 2014-06-16 | 2017-09-26 | 尤尼根公司 | 用于管理或改进骨病症、软骨病症或二者的组合物和方法 |
| TWI691716B (zh) * | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | 電漿特異性結合搭配物檢定中之信號放大 |
| CN104297482B (zh) * | 2014-09-16 | 2016-08-17 | 中山生物工程有限公司 | EB病毒VCA/NA1-IgA抗体联合检测试剂及其制备方法 |
| CN204719052U (zh) * | 2015-05-15 | 2015-10-21 | 德康润生物科技（天津）有限公司 | 联合检测结核分枝杆菌抗体的试剂盒 |
| EP3156801A1 (en) * | 2015-10-13 | 2017-04-19 | Ludwig-Maximilians-Universität München | Sicam-1 as biomarker for pain and pain intensity |
| US11340217B2 (en) * | 2016-03-09 | 2022-05-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Catalytic particles for increased sensitivity in lateral flow immunoassays |
| RS63770B1 (sr) * | 2016-04-15 | 2022-12-30 | Esm Technologies Llc | Postupak za procenu terapeutika za zglobove članaka |
| CN106370844A (zh) * | 2016-08-30 | 2017-02-01 | 吕炜锋 | 人骨代谢标志物检测双胶体金试纸条及应用其的检测装置 |
| CN107688090A (zh) * | 2017-07-17 | 2018-02-13 | 润和生物医药科技(汕头)有限公司 | 一种NTx检测试纸、试剂盒及其制备方法 |
| WO2023224993A1 (en) * | 2022-05-16 | 2023-11-23 | Xbiologix, Inc. | Rapid detection tests and methods of forming the same |
| US11747336B1 (en) * | 2022-06-30 | 2023-09-05 | Xbiologix, Inc. | Rapid detection tests with preloaded detection particles |
-
2019
- 2019-04-02 EP EP19713506.4A patent/EP3775896B1/en active Active
- 2019-04-02 JP JP2020554068A patent/JP2021520484A/ja not_active Ceased
- 2019-04-02 CN CN201980019669.6A patent/CN111868528B/zh active Active
- 2019-04-02 US US17/043,742 patent/US12123873B2/en active Active
- 2019-04-02 WO PCT/EP2019/058224 patent/WO2019192978A1/en not_active Ceased
- 2019-04-02 ES ES19713506T patent/ES2953017T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775896A1 (en) | 2021-02-17 |
| EP3775896C0 (en) | 2023-06-07 |
| CN111868528A (zh) | 2020-10-30 |
| US12123873B2 (en) | 2024-10-22 |
| US20210033605A1 (en) | 2021-02-04 |
| EP3775896B1 (en) | 2023-06-07 |
| WO2019192978A1 (en) | 2019-10-10 |
| JP2021520484A (ja) | 2021-08-19 |
| CN111868528B (zh) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2953017T3 (es) | Dispositivo de tira de inmunoensayo de flujo lateral | |
| ES2666350T3 (es) | Método y dispositivo para la detección combinada de infecciones virales y bacterianas | |
| KR102209489B1 (ko) | 바이러스 및 박테리아 감염의 복합 검출을 위한 방법 및 장치 | |
| ES2536112T3 (es) | Sistemas y métodos para determinar el porcentaje de glucohemoglobina | |
| US11867693B2 (en) | Semi-quantitative lateral-flow immunoassay for the detection of CSF leaks | |
| Cai et al. | Lateral flow immunoassay based on gold magnetic nanoparticles for the protein quantitative detection: Prostate-specific antigen | |
| WO2016191507A1 (en) | Use of fluorescence for the quick and easy determination of s-adenosylmethionine, s-adenosylhomocysteine and homocysteine | |
| CN106066399A (zh) | 检测早期糖尿病肾病的胶体金试纸条的制备方法 | |
| ES2684976T3 (es) | Biomarcadores maternos para diabetes gestacional | |
| US20110312922A1 (en) | EDTA Resistant S100A12 Complexes (ERAC) | |
| ES2363609T3 (es) | Método de diagnóstico para preeclampsia. | |
| Hong et al. | Quantitative lateral-flow immunoassay for the assessment of the cartilage oligomeric matrix protein as a marker of osteoarthritis | |
| ES2907068T3 (es) | Detección específica de isoformas de clusterina | |
| US20190041407A1 (en) | Devices, systems and methods for quantifying hemoglobin s concentration | |
| WO2012006394A2 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
| ES2352351T3 (es) | Métodos para la estratificación de la insuficiencia cardiaca. | |
| US20090181403A1 (en) | CEACAM1 Based Point-Of-Care Cancer Diagnostic | |
| US20240319180A1 (en) | Devices and methods for diagnosising thyroid medical conditions | |
| EP3308167A1 (en) | Use of fluorescence for the quick and easy determination of s-adenosylmethionine, s-adenosylhomocysteine and homocysteine | |
| UA125669C2 (uk) | Спосіб і обладнання для диференціювання вірусних інфекцій і бактеріальних інфекцій | |
| ES2744175T3 (es) | Biomarcadores suPAR no glucosilados y usos de los mismos | |
| CN107076760A (zh) | 用于评估先兆子痫的生物标志物 | |
| CN112543871A (zh) | 胰腺癌判断用的标记物 | |
| US20030059370A1 (en) | In vivo diagnostic apparatus and methods thereof | |
| US20120301897A1 (en) | Acetaminophen-protein adduct assay device and method |